PR Newswire·Jul 16, 2026, 10:09 AM ET

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 27, 2026 in Zoetis Inc. Lawsuit - ZTS

A securities class action was filed against Zoetis Inc. (NYSE: ZTS) for alleged securities fraud, covering the period from January 14, 2025, to May 6, 2026.
Wall Street analysts downgraded ZTS following four corrective disclosures between August 5, 2025, and May 7, 2026, which revealed concealed competitive erosion and safety issues.
The initial August 5, 2025 disclosure highlighted unexpected weakness in the Librela pain franchise after FDA warnings regarding seizures and deaths in dogs.
By November 4, 2025, slowing growth across key Companion Animal franchises caused ZTS shares to drop 13.8% as competitors like Elanco gained market share.
On May 7, 2026, a final disclosure regarding significant deterioration in the dermatology market triggered a 21.5% single-day stock decline of $23.91 per share.
The lawsuit alleges management concealed material risks, including declining prescription trends for Librela, share losses for Simparica Trio, Apoquel, and Cytopoint, and unsustainable growth projections.
The lead plaintiff deadline for the case is set for July 27, 2026.
Eligible investors include those who purchased ZTS securities during the class period, regardless of whether they still hold the shares or sold them at a loss.
Levi & Korsinsky LLP is representing the investors on a contingency basis with no upfront costs or fees required.